By Colin Kellaher

 

Neon Therapeutics Inc. (NTGN) on Monday said a phase 1b study of NEO-PV-01, its personal neoantigen vaccine candidate, showed prolonged and consistent improvements in progression-free survival in three distinct tumor types.

The Cambridge, Mass., clinical-stage immuno-oncology company said NEO-PV-01 in combination with Bristol-Myers Squibb Co.'s (BMY) cancer drug Opdivo improved progression-free survival in patients with advanced or metastatic melanoma, smoking-associated non-small cell lung cancer, and bladder cancer.

Neon said the study data support future randomized phase 2 development of NEO-PV-01, a vaccine that is custom-designed for each individual patient and intended to generate an anti-tumor immune response directing T cells to target particular neoantigens in the patient's tumor.

Shares of Neon, which closed Friday at $4.32, rose 13.4% in premarket trading Monday.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

July 15, 2019 08:49 ET (12:49 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Bristol Myers Squibb Charts.